These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 15096423

  • 21. Prevalence of perceived dysphonia in a geriatric population.
    Golub JS, Chen PH, Otto KJ, Hapner E, Johns MM.
    J Am Geriatr Soc; 2006 Nov; 54(11):1736-9. PubMed ID: 17087701
    [Abstract] [Full Text] [Related]

  • 22. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
    Simpson CB, Lee CT, Hatcher JL, Michalek J.
    Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
    [Abstract] [Full Text] [Related]

  • 23. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
    Meyer TK, Hu A, Hillel AD.
    Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
    [Abstract] [Full Text] [Related]

  • 24. Correlation of the Voice Handicap Index (VHI) and the Voice-Related Quality of Life Measure (V-RQOL).
    Portone CR, Hapner ER, McGregor L, Otto K, Johns MM.
    J Voice; 2007 Nov; 21(6):723-7. PubMed ID: 16887328
    [Abstract] [Full Text] [Related]

  • 25. Quality of life and voice: study of a Brazilian population using the voice-related quality of life measure.
    Behlau M, Hogikyan ND, Gasparini G.
    Folia Phoniatr Logop; 2007 Nov; 59(6):286-96. PubMed ID: 17965571
    [Abstract] [Full Text] [Related]

  • 26. Reliability of clinician-based (GRBAS and CAPE-V) and patient-based (V-RQOL and IPVI) documentation of voice disorders.
    Karnell MP, Melton SD, Childes JM, Coleman TC, Dailey SA, Hoffman HT.
    J Voice; 2007 Sep; 21(5):576-90. PubMed ID: 16822648
    [Abstract] [Full Text] [Related]

  • 27. Botulinum toxin injection for adductor spastic dysphonia: patient self-ratings of voice and phonatory effort after three successive injections.
    Aronson AE, McCaffrey TV, Litchy WJ, Lipton RJ.
    Laryngoscope; 1993 Jun; 103(6):683-92. PubMed ID: 8502104
    [Abstract] [Full Text] [Related]

  • 28. [Treatment of spasmodic dysphonia with botulinum toxin].
    Klap P, Marion MH, Perrin A, Fresnel-Elbaz E.
    Ann Otolaryngol Chir Cervicofac; 1991 Jun; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
    [Abstract] [Full Text] [Related]

  • 29. The relationship between ratings of voice quality and quality of life measures.
    Murry T, Medrado R, Hogikyan ND, Aviv JE.
    J Voice; 2004 Jun; 18(2):183-92. PubMed ID: 15193651
    [Abstract] [Full Text] [Related]

  • 30. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.
    Novakovic D, Waters HH, D'Elia JB, Blitzer A.
    Laryngoscope; 2011 Mar; 121(3):606-12. PubMed ID: 21298641
    [Abstract] [Full Text] [Related]

  • 31. Clinical evaluation of Parkinson's-related dysphonia.
    Sewall GK, Jiang J, Ford CN.
    Laryngoscope; 2006 Oct; 116(10):1740-4. PubMed ID: 17003722
    [Abstract] [Full Text] [Related]

  • 32. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia.
    Liu TC, Irish JC, Adams SG, Durkin LC, Hunt EJ.
    J Otolaryngol; 1996 Apr; 25(2):66-74. PubMed ID: 8683655
    [Abstract] [Full Text] [Related]

  • 33. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
    Shoffel-Havakuk H, Marks KL, Morton M, Johns MM, Hapner ER.
    Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
    [Abstract] [Full Text] [Related]

  • 34. Voice-related quality of life in patients with benign vocal fold lesions.
    Leeper WR, Fung K, Beaudin PG, Doyle PC.
    J Otolaryngol Head Neck Surg; 2008 Jun; 37(3):423-9. PubMed ID: 19128649
    [Abstract] [Full Text] [Related]

  • 35. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection.
    Warrick P, Dromey C, Irish JC, Durkin L, Pakiam A, Lang A.
    Laryngoscope; 2000 Aug; 110(8):1366-74. PubMed ID: 10942143
    [Abstract] [Full Text] [Related]

  • 36. Correlation of the Voice Handicap Index-10 (VHI-10) and Voice-Related Quality of Life (V-RQOL) in patients with dysphonia.
    Romak JJ, Orbelo DM, Maragos NE, Ekbom DC.
    J Voice; 2014 Mar; 28(2):237-40. PubMed ID: 24321582
    [Abstract] [Full Text] [Related]

  • 37. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 38. Electromyographic assessment of spasmodic dysphonia patients prior to botulinum toxin injection.
    Rodriquez AA, Ford CN, Bless DM, Harmon RL.
    Electromyogr Clin Neurophysiol; 1994 Jun; 34(7):403-7. PubMed ID: 7859668
    [Abstract] [Full Text] [Related]

  • 39. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
    Rosow DE, Parikh P, Vivero RJ, Casiano RR, Lundy DS.
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
    [Abstract] [Full Text] [Related]

  • 40. Botulinum toxin injections for new onset bilateral vocal fold motion impairment in adults.
    Ekbom DC, Garrett CG, Yung KC, Johnson FL, Billante CR, Zealear DL, Courey MS.
    Laryngoscope; 2010 Apr; 120(4):758-63. PubMed ID: 20213793
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.